Qiagen (QGEN) Stock
Established molecular diagnostics provider serving global research and testing. Here's the price, business snapshot, and what's worth knowing about Qiagen in August 2026.
Qiagen NV (QGEN) is an established provider of sample and assay technologies used in molecular diagnostics, life-science research and applied testing. The company's tools and kits help laboratories detect and analyse DNA, RNA and proteins — supporting areas such as infectious-disease testing, oncology, and personalised medicine. Revenue comes from recurring sales of consumables and instruments plus growing services tied to companion diagnostics and molecular tests. Geographic reach is global, exposing the business to developed and emerging market dynamics. Key catalysts include continued demand for molecular testing, expansion in oncology testing and the adoption of precision therapies. Investors should weigh these opportunities against risks: reimbursement pressure, regulatory scrutiny, competition from other diagnostics firms, foreign-exchange swings and possible volatility in instrument sales. With a market capitalisation near $10.5bn, Qiagen may suit investors seeking exposure to diagnostic technologies, but returns are not guaranteed. This is general information and not personal financial advice; consider your investment objectives and risk tolerance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying QIAGEN's stock with a target price of $50.66, indicating potential growth.
Financial Health
QIAGEN is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
QIAGEN's projected dividend yield of 0.24% is low, indicating limited returns for dividend-focused investors. If you invested $1000, you would be paid $2.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Consumables Revenue
Qiagen earns steady revenue from consumables and reagents that labs repurchase regularly, though sales can fluctuate with testing demand.
Global Diagnostics Reach
A broad international footprint gives exposure to varied markets and growth opportunities, but also brings foreign‑exchange and regional regulatory risks.
Oncology & Precision Medicine
Growth in companion diagnostics and personalised therapies could be a catalyst, while competition and reimbursement remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
